Search Results for “Amgen ” – Page 14 – media

Bayer receives approval in China for Stivarga® (regorafenib) for the second-line systemic Treatment of liver cancer

Approval based on data from the Phase III RESORCE study where Stivarga® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib)
- Source: investor.bayer
- 702
- December 14, 2017
Bayer CFDA hepatocellular carcinoma Nexavar® Stivarga®
Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products

Obsidian Therapeutics, Inc., a biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, announced the completion of a $49.5 million Series A financing to further build its technology platform and advance its lead programs toward clinical development.
- Source: Businesswire
- 557
- December 8, 2017
CAR–T Market Views Series
First Video Game Therapy Heads to FDA As Akili Touts ADHD Study Win

For the first time ever, a mobile video game used to assess and treat a disease is headed for an FDA review.
- Source: xconomy
- 490
- December 7, 2017
ADHD Attention Performance Index Company Insight video game
Japan’s PeptiDream Bags $1.11B+ R&D Pact With Bayer

Peptidream Inc. has scored another billion dollar-plus agreement to develop peptide-based therapies aimed at the treatment multiple disease targets.
- Source: Biospace
- 507
- November 21, 2017
Market Views PDC PDPS peptide-based
Boehringer bags first biosimilar approval in the EU

Boehringer Ingelheim has won its first biosimilar approval in Europe with authorisation of Cyltezo for a range of chronic inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
- Source: Pharmatimes
- 594
- November 16, 2017
arthritis biosimilar chronic Cyltezo New Approvals
Bristol-Myers, J&J sink cash into a new $95M European biotech fund

A venture capital firm in the Netherlands — backed by some big names in Big Pharma — has raised $95 million in a new fund to fuel European biotech startups.
- Source: Endpts
- 617
- November 3, 2017
diagnostics funding Market Views medical device therapeutics
NIH accelerates the development of new cancer immunotherapy strategies for more patients

The National Institutes of Health(NIH) and 11 leading biopharmaceutical companies have launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot.
- Source: nih.gov
- 551
- October 16, 2017
Market Views NIH PACT
FDA approves first cancer biosimilar

The US Food and Drug Administration(FDA) has approved Amgen’s Mvasi (bevacizumab-awwb) as a biosimilar to Roche/Genentech’s Avastin (bevacizumab) for the treatment of multiple types of cancer, making it the first biosimilar approved in the country for the treatment of cancer.
- Source: Pharmatimes
- 686
- September 18, 2017
biosimilar cancer FDA New Approvals
EU regulators review Novartis’ migraine drug

An experimental therapy being developed by Amgen and Novartis to prevent migraine has been accepted for review in the European Union.
- Source: pharmatimes
- 1,004
- June 22, 2017
antibody Clinical Trials erenumab EU New Approvals WHO

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.